中文版 | English http://www.cgenetech.com.cn
   

Pipeline

   
 

We have broad based research efforts spanning across a number of therapeutic areas.
CGeneTech is currently pursuing research programs in the following principal areas: cardiovascular and diabetes. In all of these programs, we have identified targets and compounds with demonstrated in vitro and, in some cases, in vivo activity.

Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates.

CGeneTech is conducting clinical and preclinical studies in its core focus areas, which include the following:

  • Cholesterol abnormity

           ESP-8509 recently completed

  • Renin inhibitors

           ESP-9085 recently completed target identification and design.

  • DPPIV inhibitors

          ESP-8012 completed target identification, screening, lead modification, SAR, in-vitro studies. ?Applied China and US patent.

In addition to the areas noted above, CGeneTech is continuing to explore the human genome to identify new therapeutic opportunities.

 


 
     
CGeneTech (Suzhou, China) Co., Ltd.  |  苏ICP备10105603号-1  |   WEB:www.cgenetech.com.cn
TEL: 0086-512-62956962  |   FAX: 0086-512-62956961  |  CONTACT: info@cgenetech.com.cn or sales@cgenetech.com.cn